Search research articles
Contact Us
Filters
Showing results (21-30 of 87) with videos related to
Page
of 9
Sort By:
Trends in Pharmacological Sciences
|
October 28, 2021
Engineered antibody fusion proteins for targeted disease therapy
Aliyah B Silver, Elissa K Leonard, Joseph R Gould, et al.
Plos Computational Biology
|
June 7, 2024
Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors
Christina M P Ray, Huilin Yang, Jamie B Spangler, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
November 24, 2023
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases
Luke M Tomasovic, Kathy Liu, Derek VanDyke, et al.
Current Opinion in Biotechnology
|
September 30, 2022
Biologics-based degraders - an expanding toolkit for targeted-protein degradation
Derek VanDyke, Jonathan D Taylor, Kyle J Kaeo, et al.
Immunological Reviews
|
June 7, 2023
Engineering the IL-4/IL-13 axis for targeted immune modulation
Zachary J Bernstein, Anjali Shenoy, Amy Chen, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 29, 2023
Design and Construction of Antibody Fusion Proteins Incorporating Variable New Antigen Receptor (VNAR) Domains
Seth D Ludwig, Angela Zhu, Ankith P Maremanda, et al.
The Journal of Biological Chemistry
|
August 8, 2019
A strategy for the selection of monovalent antibodies that span protein dimer interfaces
Jamie B Spangler, Ignacio Moraga, Kevin M Jude, et al.
Current Protocols
|
May 22, 2024
Cytokine/Antibody Fusion Protein Design and Evaluation
Charina S Fabilane, A Carson Stephenson, Elissa K Leonard, et al.
Journal of the American Chemical Society
|
June 8, 2022
Antibody-Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers
Elissa K Leonard, Miguel Aller Pellitero, Boris Juelg, et al.
Journal of Molecular Biology
|
June 19, 2012
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression
Jamie B Spangler, Mandana T Manzari, Elizabeth K Rosalia, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 87) with videos related to
Sort By:
Page
of 9
Trends in Pharmacological Sciences
|
October 28, 2021
Engineered antibody fusion proteins for targeted disease therapy
Aliyah B Silver, Elissa K Leonard, Joseph R Gould, et al.
Plos Computational Biology
|
June 7, 2024
Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors
Christina M P Ray, Huilin Yang, Jamie B Spangler, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
November 24, 2023
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases
Luke M Tomasovic, Kathy Liu, Derek VanDyke, et al.
Current Opinion in Biotechnology
|
September 30, 2022
Biologics-based degraders - an expanding toolkit for targeted-protein degradation
Derek VanDyke, Jonathan D Taylor, Kyle J Kaeo, et al.
Immunological Reviews
|
June 7, 2023
Engineering the IL-4/IL-13 axis for targeted immune modulation
Zachary J Bernstein, Anjali Shenoy, Amy Chen, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 29, 2023
Design and Construction of Antibody Fusion Proteins Incorporating Variable New Antigen Receptor (VNAR) Domains
Seth D Ludwig, Angela Zhu, Ankith P Maremanda, et al.
The Journal of Biological Chemistry
|
August 8, 2019
A strategy for the selection of monovalent antibodies that span protein dimer interfaces
Jamie B Spangler, Ignacio Moraga, Kevin M Jude, et al.
Current Protocols
|
May 22, 2024
Cytokine/Antibody Fusion Protein Design and Evaluation
Charina S Fabilane, A Carson Stephenson, Elissa K Leonard, et al.
Journal of the American Chemical Society
|
June 8, 2022
Antibody-Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers
Elissa K Leonard, Miguel Aller Pellitero, Boris Juelg, et al.
Journal of Molecular Biology
|
June 19, 2012
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression
Jamie B Spangler, Mandana T Manzari, Elizabeth K Rosalia, et al.
Page
of 9